AbbVie To Acquire Capstan For Up To $2.1B

Reuters Legal (6/30, Santhosh) reports AbbVie announced Monday it will “acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases. The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira [adalimumab], lost patent protection.” Reuters adds that Capstan “develops CAR-T therapies, which use a patient’s own immune cells, specifically T-cells, to fight diseases. Its main drug, CPTX2309, is currently in early-stage development for the treatment of autoimmune diseases.”